Literature DB >> 20173159

Hydrodisplacement in the percutaneous cryoablation of 50 renal tumors.

Kale D Bodily1, Thomas D Atwell, Jayawant N Mandrekar, Michael A Farrell, Matthew R Callstrom, Grant D Schmit, J William Charboneau.   

Abstract

OBJECTIVE: The purpose of this article is to describe the technique, safety, and effectiveness of percutaneous hydrodisplacement during the course of percutaneous renal cryoablation.
MATERIALS AND METHODS: We retrospectively reviewed our experience in performing percutaneous hydrodisplacement during the cryoablation of renal tumors. In this subset of patients, we addressed tumor location within the kidney, tumor position relative to critical structures, effectiveness of hydrodisplacement, and complications in performing this adjunct technique. Comparisons between the two groups were made using Wilcoxon's rank sum test or chi-square test, as appropriate.
RESULTS: Hydrodisplacement was attempted 52 times in 50 (24%) of 206 percutaneous renal tumor cryoablations. Tumors that were located anteriorly (p < 0.0001) or in the lower pole (p = 0.001) of the kidney were more likely to require hydrodisplacement. The colon required displacement most often (n = 41), followed by the body wall (n = 3), duodenum (n = 2), jejunum and ileum (n = 2), ureter (n = 1), and psoas muscle (n = 1). There was a single complication of hemorrhage resulting from injury to an intercostal artery branch that required termination of the procedure before fluid infusion. When fluid was infused, the critical structure was displaced in 50 (96%) of 52 attempts, displacing the critical structure from its initial location by a mean distance of 16 mm (range, 3-46 mm). Both failures occurred early in our experience with hydrodisplacement, and both required balloon displacement.
CONCLUSION: Hydrodisplacement is a safe, effective, and commonly needed technique for displacement of critical structures before percutaneous cryoablation of renal tumors, particularly for tumors located anteriorly or in the lower pole of the kidney.

Entities:  

Mesh:

Year:  2010        PMID: 20173159     DOI: 10.2214/AJR.08.1570

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  14 in total

Review 1.  Management and prevention of renal ablative therapy complications.

Authors:  G Igor Pinkhasov; Jay D Raman
Journal:  World J Urol       Date:  2010-04-10       Impact factor: 4.226

2.  Ureteral protection during microwave ablation of renal cell carcinoma: combined use of pyeloperfusion and hydrodissection.

Authors:  Katayoun Samadi; Ronald S Arellano
Journal:  Diagn Interv Radiol       Date:  2018-11       Impact factor: 2.630

3.  Thermoablation of Renal Masses: The Urologist's Perspective.

Authors:  Phillip H Abbosh; Sam B Bhayani
Journal:  Semin Intervent Radiol       Date:  2011-12       Impact factor: 1.513

4.  High-powered microwave ablation of t1a renal cell carcinoma: safety and initial clinical evaluation.

Authors:  Anna J Moreland; Timothy J Ziemlewicz; Sara L Best; J Louis Hinshaw; Meghan G Lubner; Marci L Alexander; Christopher L Brace; Douglas R Kitchin; Sean P Hedican; Stephen Y Nakada; Fred T Lee; E Jason Abel
Journal:  J Endourol       Date:  2014-07-02       Impact factor: 2.942

Review 5.  Renal ablation update.

Authors:  Vishal Khiatani; Robert G Dixon
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

6.  Percutaneous Cryoablation for Local Control of Metachronous Inguinal Lymph Node Metastases.

Authors:  Francois Cornelis; Philip B Paty; Constantinos T Sofocleous; Stephen B Solomon; Jeremy C Durack
Journal:  Cardiovasc Intervent Radiol       Date:  2014-07-01       Impact factor: 2.740

7.  Efficacy of percutaneous cryoablation of renal cell carcinoma in older patients with medical comorbidities: Outcome study in 70 patients.

Authors:  Erich K Lang; Kan Karl Zhang; Quan Nguyen; Leann Myers; Mahamed Allaf; Ivan Colon
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

Review 8.  Image-Guided Thermal Ablative Therapies in the Treatment of Sarcoma.

Authors:  Scott M Thompson; John J Schmitz; Grant D Schmit; Matthew R Callstrom; Anil Nicholas Kurup
Journal:  Curr Treat Options Oncol       Date:  2017-04

9.  Design and validation of a thermoreversible material for percutaneous tissue hydrodissection.

Authors:  Alexander Johnson; Anthony Sprangers; Patrick Cassidy; Sean Heyrman; J Louis Hinshaw; Meghan Lubner; John Puccinelli; Chris Brace
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2013-11       Impact factor: 3.368

10.  Efficacy of antegrade and retrograde warm saline pyeloperfusion during renal cryoablation for ureteral preservation.

Authors:  Benjamin West; Mohamed Keheila; Jason C Smith; Alexander Erskine; Samuel R Abourbih; Nazih Khater; D Duane Baldwin
Journal:  Turk J Urol       Date:  2018-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.